UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 28, 2012
ALIMERA SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-34703 | 20-0028718 | ||
(State or other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
6120 Windward Parkway Suite 290 Alpharetta, Georgia |
30005 | |||
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: (678) 990-5740
Not Applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. Entry into a Material Definitive Agreement.
On November 28, 2012, Alimera Sciences, Inc. (Alimera U.S.) entered into a Master Services Agreement (the Agreement) with Quintiles Commercial Europe Limited. Under the Agreement, Quintiles Commercial Europe Limited and its affiliates (collectively, Quintiles Commercial) will provide certain services to Alimera U.S. and its affiliates (collectively, Alimera) in relation to the commercialization of ILUVIEN®, Alimeras product for the treatment of chronic diabetic macular edema considered insufficiently responsive to available therapies, in certain countries in Europe. Such services may include marketing, brand management, sales promotion and detailing, market access, pricing and reimbursement support, regulatory, medical science liaison and communications and/or other advisory services. Pursuant to the Agreement, Quintiles Commercial and Alimera will mutually agree upon the details of the services to be provided (such as the type, scope, fees, payment terms, and schedule) in individual written project orders (each, a Project Order).
The Agreement expires on August 6, 2017. However, if any Project Order remains in effect upon the expiration of the Agreement, the Agreement will continue in effect solely as it applies to such Project Order until the termination or expiration of such Project Order. Each party may terminate the Agreement (and all active Project Orders) for an uncured material breach of the Agreement by the other party or upon bankruptcy or insolvency of the other party.
On November 28, 2012, Alimera U.S. and Quintiles Commercial Germany GmbH (Quintiles Commercial Germany) entered into the first Project Order under the Agreement with respect to the provision of services related to the recruitment, employment, deployment and administration of a commercialization team in Germany (the German Project Order). The term of the German Project Order expires on December 31, 2015. Alimera U.S. and Quintiles Commercial Europe Limited expect to enter into substantially similar Project Orders regarding the provision of similar services in the United Kingdom and France. Quintiles Commercial began interviewing and hiring personnel in Germany, the United Kingdom and France in September in anticipation of the execution of project orders in Germany, the United Kingdom and France.
Pursuant to the Project Orders, Alimera U.S. will pay Quintiles Commercial an amount that covers (i) certain of Quintiles Commercials costs in providing such services (e.g., costs associated with salaries, bonuses, vehicles, insurance and other benefits, equipment, recruitment, and management and administration) and (ii) a mutually agreed upon margin on the total of such costs. Alimera U.S. will also reimburse Quintiles Commercial for certain pass-through expenses (e.g., travel-related expenses).
Alimera U.S. will have the right to terminate a Project Order on written notice to Quintiles Commercial in the event of certain standard termination events relating to the marketing of ILUVIEN® in the applicable jurisdiction, and each party may terminate a Project Order for an uncured material breach of the Project Order by the other party, in each case, subject to the payment of certain wind down costs by Alimera U.S.
A copy of the Agreement and the form of Project Order will be filed as an exhibit to Alimera U.S.s annual report on Form 10-K for the year ending December 31, 2012. The foregoing description of the Agreement and the form of Project Order is qualified in its entirety by reference to the full text of such exhibits.
Item 8.01. Other Events.
On December 4, 2012, the Company issued a press release announcing the signing of the Agreement and the German Project Order which is filed as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 8.01 of this Current Report on Form 8-K and the press release furnished as Exhibit 99.1 hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
Description | |
99.1 | Press Release of Alimera Sciences, Inc. dated December 4, 2012. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALIMERA SCIENCES, INC. | ||||
By: | /s/ RICHARD S. EISWIRTH, JR. | |||
Name: | Richard S. Eiswirth, Jr | |||
Title: | Chief Operating Officer and Chief Financial Officer |
Dated: December 4, 2012
Exhibit 99.1
FOR IMMEDIATE RELEASE
For press inquiries: Katie Brazel, Fleishman-Hillard for Alimera Sciences 404-739-0150 Katie.Brazel@fleishman.com |
For investor inquiries: John Mills, ICR for Alimera Sciences 310-954-1105 John.Mills@ICRINC.com |
ALIMERA SCIENCES SIGNS AGREEMENT WITH QUINTILES FOR EUROPEAN
COMMERCIAL LAUNCH OF ILUVIEN®
ATLANTA, December 4, 2012 Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced it has signed a Master Services Agreement with Quintiles Commercial Europe Ltd. (Quintiles) for the commercial launch of ILUVIEN® in certain European countries. ILUVIEN is Alimeras product for the treatment of chronic diabetic macular edema considered insufficiently responsive to available therapies.
We believe this strategic collaboration with Quintiles will be pivotal in achieving a successful launch of ILUVIEN in Europe, and at the outset, our initial launch market of Germany, said Dan Myers, president and chief executive officer, Alimera. Quintiles broad track-record in the implementation and execution of multi-country, European commercialization projects made the organization an ideal services provider for Alimera in support of the commercial launch of ILUVIEN in Europe.
Services provided by Quintiles under the Master Services Agreement may include marketing, brand management, sales promotion and detailing, market access, regulatory, medical science liaison and communications and advisory services in certain European countries. Under this agreement, Alimera and Quintiles will enter into individual project orders that will specify the services to be provided.
The German Project Order, the first under the Master Services Agreement, was signed November 28, 2012. Under this project order, Quintiles Commercial Germany GmbH will provide services related to recruitment, employment, deployment and administration of the ILUVIEN commercialization team in Germany through December 31, 2015. Alimera and Quintiles expect to sign additional project orders for similar services in the United Kingdom and France. Quintiles began interviewing and hiring personnel in Germany, the United Kingdom and France in September in anticipation of the execution of project orders in all three countries.
This relationship leverages Quintiles core commercial talent and strengths. In addition, as the healthcare landscape has become more complex, it is increasingly important to engage with multiple stakeholders across the patient pathway. We have the broad expertise and experience to make this happen, said Chris Pepler, senior vice president, Commercial Solutions at Quintiles. As Alimera Sciences enters these critical markets, we are excited to partner with them to help drive the success of ILUVIEN in the European ophthalmic market.
About Quintiles
Quintiles is the worlds leading provider of biopharmaceutical services. With a network of more than 27,000 professionals working in more than 80 countries, Quintiles has helped develop or commercialize all of the top 50 best selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, Quintiles helps biopharmaceutical and health sciences customers navigate the increasingly complex landscape with more predictability to enable better outcomes.
About ILUVIEN®
ILUVIEN (190 micrograms fluocinolone acetonide intravitreal implant in applicator) is a sustained release intravitreal implant used to treat vision impairment associated with chronic DME considered insufficiently responsive to available therapies. Each ILUVIEN implant provides a therapeutic effect of up to 36 months by delivering sustained sub-microgram levels of fluocinolone acetonide (FAc). ILUVIEN is injected in the back of the patients eye to a position that takes advantage of the eyes natural fluid dynamics. The applicator employs a 25-gauge needle, which allows for a self-sealing wound. In the FAME Study, the most frequently reported adverse drug reactions included cataract operation, cataract and increased ocular pressure.
In July 2010, Alimera submitted a Marketing Authorization Application (MAA) to seven European countries via the Decentralized Procedure (DCP) with the Medicines and Healthcare products Regulatory Agency of the U.K. (MHRA) serving as the Reference Member State (RMS). The MAA included data from two Phase 3 pivotal clinical trials (collectively known as the FAME Study) for ILUVIEN conducted by Alimera. The trials involved 956 patients in sites across the United States, Canada, Europe and India to assess the efficacy and safety of ILUVIEN for the treatment of DME. At the end of the DCP, a consensus was reached by the RMS and the other six countries that the MAA for ILUVIEN was approvable. To date, five of the seven countries, Austria, the United Kingdom, Portugal, France and Germany have granted national licenses for ILUVIEN. ILUVIEN has not been approved by the United States Food and Drug Administration.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.
Forward Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimeras commercial plans for ILUVIEN in Germany, the UK and France. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, uncertainty as to Alimeras and Quintiles ability to commercialize, and market acceptance of, ILUVIEN in the EU, as well as other factors discussed in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of Alimeras Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, which are on file with the Securities and Exchange Commission (SEC) and available on the SECs website at www.sec.gov. In addition to the risks described above and in Alimeras Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimeras results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
# # #
`;%[
MA(G9;Y.]^&3/+=3MOEYW$66PX D%9$;Z\,F-U\:^,_:DQDVQD9^XT-SE6S'5`Q5G<[E6?E[XX=K
M]7SA54;3J11$>8@4!XKW.2X)N7,N[.-G^3M/\!(W!+"$M2'5-!/ICHZ,IO#Z
M9I`KWUME9_\`4)5]@B%@OB/,`2N`-\^-=U5#3 )&133?N-)'O"1"2=T
MY],6-RQ5%3J=N^5*TFD89*6D2,PI7O*)V;,!O@F'`WBS1X+*6.JYEW&M_P`6
M6YJ5Y5\C4RRTB?;F(13N1%GB'<.^$A3@)>\F@[$Q!_>G`!#F'$VV7"HM-Q8N
ME&D>&EJ^55';_+Z-1.4R#J1
M:D5:G2"%H84H)2V#LD6RE
:V5-0E*CT(G-P]65`.
M,%J]7$6JU/UYE-MHD#XVQ(EOQE@-NZ`<^+S=Y3=H>SZD8\O6U3?]9LKW27M.
M7
**^F]4S],IP/+<2E07(9LV!ET9H.70VOE;
M+=JH;)TOL#5QT$_&C>$Z/"9_1N:E8[Y?>Y*NK.3*T*G."UU].9T0R`*:=8"'
M`)KW.6'@G!;6KVFXE!X9<73E&>6!4$IS9>D#&+U3)U3QTFI71>'GW@D+S'LF
M9133S.>*?,/DID]OK[%>2L;X_3Q"TR(WFBWYO97!Y0UR6J*C$T6-?8/2E*T"
MO*]WN](CW"].O/2\\EN;-IY9HKT72DJ*DU?#R\)2!ER9IYLW3/"4<76FDZO4
MRF%4KK;8:"IY@3.
-W3%:1;UDCI%U*3M*GGKYN8\DL<`4.)@,8/G:``<
M16UK